Natera, Inc.(NTRA)Company Profile & Business
NASDAQ

Company Profile

Business overview, scale, and footprint

Company NameNatera, Inc.
Ticker SymbolNTRA
ExchangeNMS
SectorHealthcare
IndustryDiagnostics & Research
Employees6,135
CEOMr. Steven Leonard Chapman
Founded2003
HeadquartersAustin, TX, United States
CountryUnited States
Websitenatera.com
Next Earnings DateNov 5, 2026

Business Overview

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions.

In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services.

The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company has a collaboration with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma.

The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.

Insider Transactions

Open-market activity and option exercises

Insider Activity Summary

Insider trading activity for Natera, Inc. (NTRA) between Oct 20, 2025 and Oct 1, 2026 consists of 333 total transactions. Among these, company executives and board members conducted 199 buys (totaling 2,451,292 shares) and 134 sells (totaling 275,092 shares). This activity resulted in a net change of 2,176,200 shares, reflecting net buying interest with an estimated net acquisitions value of $393.00M.

333 insider transactions found. Showing 10 of 333 transactions.

Show:entries
Insider NameRelation to CompanyShares ChangedPriceTransaction Date
Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS-954$413.11Oct 1, 2026
Chapman Steven LeonardCEO AND PRESIDENT-1,273$413.31Oct 1, 2026
Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS-1,846$415.07Oct 1, 2026
Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS-200$411.62Oct 1, 2026
Sheena JonathanCO-FOUNDER-110$390.42Sep 23, 2026
Sheena JonathanCO-FOUNDER-220$390.52Sep 23, 2026
Sheena JonathanCO-FOUNDER-2,846$387.74Sep 23, 2026
Sheena JonathanCO-FOUNDER-2,734$387.65Sep 23, 2026
Sheena JonathanCO-FOUNDER-2,320$389.69Sep 23, 2026
Sheena JonathanCO-FOUNDER-2,300$386.64Sep 23, 2026
Page 1 of 34 (333 total transactions)